Buprenorphine Drug Profile - Portage College Paramedic Program

Drug Identification and Overview

  • Generic Name: buprenorphine
  • Trade Names: Belbuca, Brixadi, Buprenex, Butrans, Sublocade
  • Classification: Opioid agonist-antagonist
  • Supplied Formulations:
    • Variety of tablet dosing including buccal films
    • Subcutaneous (SUBQ\text{SUBQ}) extended-release solutions for injection
    • Sublingual (SL\text{SL}) tablets
    • Transdermal patches
  • Institutional Origin: Portage College Paramedic Program (Box 417, Lac La Biche, AB T0A2C0)

Actions and Pharmacodynamics

  • Mechanism of Action:
    • Binds to opiate receptors within the central nervous system (CNS\text{CNS}).
    • Alters the perception of pain and the physiological response to pain.
    • Exhibits partial antagonist properties at both mu (μ\mu) and kappa (κ\kappa) receptors.
    • Note on Protocol Updates: The description "Partial agonist at the mu receptors and an antagonist at the kappa receptors" was explicitly removed from current guidelines.

Indications and Physician Order Requirements

  • Mandatory Order Requirement: All uses of buprenorphine require explicit physician orders.
  • Clinical Indications:
    • Moderate to severe acute pain.
    • Pain control for patients with a documented history of opioid addiction.
    • Pain control for severe chronic pain in patients requiring continuous long-term pain management when alternative treatment options (non-opioid medications) are inadequate.
    • Suppression of opioid withdrawal symptoms.

Dosage and Administration Guidelines

  • Patient Age Restriction: Adult Only
  • Analgesia Indications:
    • Intravenous / Intramuscular (IV/IM\text{IV/IM}): 0.3 mg0.3\,\text{mg} every 4–6 hours4\text{--}6\,\text{hours} as needed.
    • Buccal Soluble Film: 75 mcg75\,\text{mcg} film daily or every 12 hours12\,\text{hours}.
  • Opioid Use Disorder Indications:
    • Sublingual (SL\text{SL}): 8 mg8\,\text{mg} once daily.
    • Subcutaneous (SUBQ\text{SUBQ}): Administered as prescribed via physician (doses provided per month).

Contraindications

  • Known hypersensitivity to buprenorphine or any formulation component.
  • Pediatric patients under the age of 18 years18\,\text{years}.
  • Pregnancy and breastfeeding.
  • Gastrointestinal (GI\text{GI}) obstruction or ileus obstruction.
  • Significant respiratory depression.
  • QTQT prolongation.
  • Concurrent use of Class I or Class III antiarrhythmics.

Precautions and Risk Factors

  • Central Nervous System & Respiratory Interactions:
    • Concurrent use with benzodiazepines, alcohol, or other CNS\text{CNS} depressants can result in severe respiratory depression.
    • Compromised respiratory function, including Chronic Obstructive Pulmonary Disease (COPD\text{COPD}), Cor pulmonale, and hypoxia.
  • Neurological & Systemic Conditions:
    • Increased intracranial pressure (ICP\text{ICP}).
    • Seizure history.
    • Adrenal insufficiency.
    • Elderly patients.
  • Organ System Impairments (Requiring Dosage Adjustment):
    • Renal disease or renal impairment.
    • Hepatic disease, alcoholism, or acute pancreatitis: Decrease dose by 12\frac{1}{2}.
  • Cardiovascular & Electrolyte Derangements:
    • Uncorrected electrical/electrolyte imbalances (hypokalemia, hypomagnesemia, hypocalcemia).
    • Unstable heart failure.
    • Unstable atrial fibrillation.
    • Myocardial ischemia.
    • Symptomatic bradycardia.
    • Concurrent use of drugs that prolong QTQT intervals.
  • Specific Drug-Drug Interactions:
    • Monoamine Oxidase (MAO) Inhibitors: Patients taking MAO\text{MAO} inhibitors within the past 14 days14\,\text{days} require a dose reduction of 12\frac{1}{2}.
    • Serotonergic Agents: Concurrent use with drugs affecting serotonergic systems increases the risk of Serotonin Syndrome. These agents include:
    • Selective Serotonin Reuptake Inhibitors (SSRIs\text{SSRIs})
    • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs\text{SNRIs})
    • MAO\text{MAO} inhibitors
    • Tricyclic Antidepressants (TCAs\text{TCAs})
    • Trazodone
    • Mirtazapine
    • Serotonin receptor antagonists
    • Linezolid
    • Methylene blue
    • Triptans

Clinical Monitoring and Special Notes

  • Adverse Effects & Vital Sign Monitoring:
    • Buprenorphine can induce sedation, respiratory depression, and hypotension.
    • Mandates continuous monitoring of Level of Consciousness (LOC\text{LOC}), vital signs, respiratory rate (RR\text{RR}), and pain score.
    • Continuous oxygen saturation (SpO2\text{SpO}_2) monitoring is strictly required.
  • Clinical Context & Availability:
    • Buprenorphine is a newer medication and continues to be evaluated for specific clinical scenarios, such as hepatic impairment.
    • Subcutaneous (SC\text{SC}) doses are reserved for specialized cases managed through hospital settings and represent a relatively new administration pathway in Canada.

Reference Standards and Revisions

  • References: Reference 1 (page 318), Reference 4 (pages 249--254), Reference 5 (page 174), Reference 12 (pages 990--991), Alberta Health Services (AHS\text{AHS}) Parenteral Manual (October 20, 2023).
  • Revision Date: Revised April 2025.